cancer_cell_division_1

New cancer drug? Therapy stalls cell growth

U. PITTSBURGH (US) — When cancer cells are deprived a key protein, the cells can’t divide properly and the cancer stops growing.

“This is the first time anyone has explained how altering this protein at a key stage in cell reproduction can stop cancer growth,” says Bennett Van Houten, professor of molecular pharmacology at the University of Pittsburgh Cancer Institute and senior author of a study published in the Journal of Cell Science.

“Our hope is that this discovery will spur the development of a new type of cancer drug that targets this process and could work synergistically with existing drugs.”

All cells have a network of mitochondria, which are tiny structures inside cells that are essential for energy production and metabolism. Dynamin-related protein 1 (Drp1) helps mitochondria undergo fission, a process by which they split themselves into two new mitochondria.

In breast or lung cancer cells made to be deficient in Drp1, the researchers observed a huge network of highly fused mitochondria. These cancer cells appear to have stalled during a stage in cell division called G2/M.

Unable to divide into new cells, the cancer growth stops. Those cells that do try to divide literally tear their chromosomes apart, causing more stress for the cell.

“Once we revealed this process for halting cancer cell growth by knocking out Drp1, we began looking into existing compounds that might utilize a similar mechanism,” says Van Houten. “Now that we know affecting mitochondria in this manner inhibits cell growth, we could target drugs to this biological process to treat cancer.”

The researchers found a compound called Mdivi-1 that makes cancer cells behave much the way they do when deficient in Drp-1. When used in combination with cisplatin, a drug already used to treat many solid cancers, rapid cell death can be induced in a wide range of cancer cells. This means that Mdivi-1 makes cisplatin work better.

Mdivi-1 is being tested in cancer cells in a laboratory setting. Those tests show that, while the compound acts as though it is depriving cancer cells of Drp1, it is actually using a different mechanism.

“To me, that’s the serendipity of science, and it’s really exciting,” says Van Houten, who hopes eventually to move his laboratory tests on Mdivi-1 to clinical trials. “We were on the hunt for a drug that could make cancer cells deficient in Drp1 and, instead, we found a new cancer therapy that seems to work really well.”

The Pennsylvania Department of Health, PA CURE, and the National Institutes of Health funded the study.

Source: University of Pittsburgh

chat3 Comments

You are free to share this article under the Creative Commons Attribution-NoDerivs 3.0 Unported license.

3 Comments

  1. Alicia

    Awesome

  2. Frank

    Sounds great, although it does make me wonder if there is collateral damage for non-cancerous cells that would also want to divide.

  3. FreeSmarts

    I think Dr.Chachoua mentioned that the cancer cell has a molecular characteristic thats different from healthy cells. So, they’re targeted by chemistry; i.e. magnetisms…

    Chemistry used to identify unique targets is old school… Getting this knowledge to the public, …that’s science!
    Example:
    “Sinai Medical Center was found guilty, by a Los Angeles jury, of a medical conspiracy.”

    Tell them, ” Keeping life saving medical science from reaching the US American
    people, who are in dire need, is immoral.”

    Please, help fight tyranny that’s developed by the plot of bureaucrats!

We respect your privacy.